Eli Lilly: diabetes drug meets trial goal
(CercleFinance.com) - US biopharmaceutical company Eli Lilly and German partner Boehringer Ingelheim said on Thursday that their anti-diabetic treatment met its primary goal in a clinical trial.
The study met its primary endpoint, with Tradjenta demonstrating similar cardiovascular safety compared with placebo.
The trial included 6,979 adults with type-2 diabetes and high cardiovascular risk, the companies said.
Separately, Lilly said the U.S. label for once-weekly Trulicity has been updated to show the medicine's safety and efficacy in people with type-2 diabetes who have moderate to severe chronic kidney disease.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The study met its primary endpoint, with Tradjenta demonstrating similar cardiovascular safety compared with placebo.
The trial included 6,979 adults with type-2 diabetes and high cardiovascular risk, the companies said.
Separately, Lilly said the U.S. label for once-weekly Trulicity has been updated to show the medicine's safety and efficacy in people with type-2 diabetes who have moderate to severe chronic kidney disease.
Copyright (c) 2018 CercleFinance.com. All rights reserved.